Business Overview: Avantor, Inc. (NYSE: AVTR)

---

Executive Summary

Avantor, Inc. is a global provider of mission-critical products, services, and solutions to customers in the life sciences and advanced technology industries. Headquartered in Radnor, Pennsylvania, Avantor was built through the combination of VWR International (a century-old laboratory products distributor) and Avantor Performance Materials, and went public on the NYSE in 2019 backed by New Mountain Capital.

Avantor generates roughly $6.5-7 billion in annual revenue, serving biopharma, healthcare, education/government, and advanced-technology customers with a mix of distributed lab consumables/equipment and proprietary, high-margin materials and single-use bioprocessing components.

---

1. Core Business Model & How They Work

Avantor operates a hybrid model: a high-volume distribution business (millions of SKUs from thousands of manufacturers, akin to a specialized lab-supplies wholesaler) layered with a proprietary manufacturing business making its own consumable materials used directly in biopharmaceutical production and research.

[ Proprietary Manufacturing: Filtration, Single-Use Bioprocessing, Chemicals ]
                          +
[ Distribution: Lab Equipment, Chemicals, Consumables from 3rd-party Suppliers ]
                          ➡️
[ Global Sales/Service Reps + eCommerce Platform ]
                          ➡️
[ Biopharma, Healthcare, Education/Government, Advanced Technology Customers ]

Key Operational Drivers

1. Distribution Scale: Avantor's legacy VWR distribution network gives it broad reach into academic, government, and biopharma lab customers who value one-stop procurement across a huge catalog.
2. Proprietary, Validated Bioprocessing Products: Products like single-use bags, filtration media, and chromatography resins used directly in biologics manufacturing are qualified into customers' regulatory-approved manufacturing processes, making them extremely sticky once designed in.
3. Global Regulatory & Quality Infrastructure: Operating in a GMP/regulated environment requires quality systems and manufacturing certifications that take years to build and validate.
4. M&A-Driven Portfolio Expansion: Avantor has historically grown its proprietary materials portfolio and geographic reach through acquisitions layered onto the VWR distribution backbone.

---

2. Business Segments

• Laboratory Solutions: The larger segment — distribution of lab equipment, chemicals, production materials, and clinical/research services to biopharma, healthcare, education, and government customers.
• Bioscience Production: The smaller, higher-margin, more proprietary segment — manufacturing of single-use bioprocessing technologies, filtration and purification products, and cell culture media used directly in biologics and vaccine production.

---

3. Product Portfolio & Revenue Drivers

---

4. Competitive Landscape

                     BROAD DISTRIBUTION BREADTH
                                     │
              Avantor (AVTR / VWR)  │  Thermo Fisher Scientific
                                     │
   NARROW ─────────────────────────┼───────────────────────── BROAD
   PROPRIETARY MATERIALS DEPTH      │              PROPRIETARY MATERIALS DEPTH
                                     │
        Regional lab distributors   │      Merck KGaA (MilliporeSigma),
        (Fisher regional resellers) │      Danaher (Cytiva), Sartorius

Competitors by Domain

Lab Supply Distribution

• Key Competitors: Thermo Fisher Scientific (Fisher Scientific channel), and numerous regional/specialty distributors.
• Dynamics: Thermo Fisher is far larger overall and competes directly across nearly the entire Avantor distribution catalog; Avantor differentiates on service model and its "ProcureFlow"/eCommerce platform.

Bioprocessing Materials

• Key Competitors: Danaher's Cytiva, Merck KGaA's MilliporeSigma (Sigma-Aldrich), Sartorius, Thermo Fisher's bioproduction division.
• Dynamics: This is the more attractive, higher-margin, higher-moat part of Avantor's business, where products are qualified into regulated biologics manufacturing processes — competition is intense among a handful of large players, but incumbency and validation lock-in matter enormously.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Regulatory validation lock-in in Bioscience Production: Once a biopharma customer validates Avantor's filter or single-use component into an FDA-regulated manufacturing process, switching suppliers requires costly and time-consuming re-validation, creating genuine stickiness.
• Distribution scale and catalog breadth: The VWR-derived network gives Avantor a broad, entrenched customer base across academic, government, and biopharma labs.
• Global GMP manufacturing and quality infrastructure: A meaningful barrier to entry for the proprietary materials business.

Strategic Risks & Vulnerabilities

1. Biopharma R&D and biotech funding cyclicality: Demand, especially in Bioscience Production, is sensitive to biotech capital-raising cycles and big pharma R&D spending.
   • Mitigation Strategy: Diversification across academic, government, and healthcare end markets that are less cyclical than biotech funding.
2. High leverage from its private-equity/LBO origins: Avantor carries meaningfully higher leverage than pure-play peers like Thermo Fisher or Danaher.
   • Mitigation Strategy: Continued free cash flow generation directed toward debt paydown.
3. Intense competition from larger, better-capitalized peers: Thermo Fisher, Danaher, and Merck KGaA all have greater scale and R&D budgets.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Avantor's strategic value lies in the combination of a broad, entrenched lab-distribution franchise with a smaller but structurally advantaged bioprocessing materials business, where regulatory validation creates real switching-cost moats that are rare in distribution-heavy business models.

The company's central long-term challenge is converting mix shift toward Bioscience Production — its highest-margin, highest-moat segment — while managing a balance sheet still working through leverage from its private-equity origins, all in a biopharma end market whose R&D and capital-raising cycles Avantor does not control.